NASDAQ:INO Inovio Pharmaceuticals (INO) Stock Price, News & Analysis $1.45 -0.06 (-3.97%) Closing price 04:00 PM EasternExtended Trading$1.34 -0.11 (-7.59%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About Inovio Pharmaceuticals Stock (NASDAQ:INO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Inovio Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.41▼$1.5150-Day Range$0.60▼$1.8952-Week Range$0.56▼$2.72Volume14.20 million shsAverage Volume4.85 million shsMarket Capitalization$149.93 millionP/E RatioN/ADividend YieldN/APrice Target$5.67Consensus RatingModerate Buy Company Overview Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells. Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases. The company has also developed INO-4800, an investigational DNA vaccine candidate for COVID-19. Its technology platform includes CELLECTRA, a proprietary device and electroporation system designed to improve the delivery of DNA medicines. Founded in 1983 as Genetronics, the company adopted the name Inovio Pharmaceuticals in 2009. Inovio is headquartered in Plymouth Meeting, Pennsylvania, and conducts research and clinical development activities through collaborations and trials in the United States and other international markets. Its products remain primarily investigational and are subject to regulatory review.AI Generated. May Contain Errors. Read More Inovio Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreINO MarketRank™: 2.961822660095 of 5 starsInovio Pharmaceuticals scored higher than 59% of companies evaluated by MarketBeat, and ranked 377th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingInovio Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialInovio Pharmaceuticals has a consensus price target of $5.67, representing about 289.5% upside from its current price of $1.46.Amount of Analyst CoverageInovio Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Inovio Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($0.74) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inovio Pharmaceuticals is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inovio Pharmaceuticals is -1.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInovio Pharmaceuticals has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Inovio Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.96% of the float of Inovio Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInovio Pharmaceuticals has a short interest ratio ("days to cover") of 6.94.Change versus previous monthShort interest in Inovio Pharmaceuticals has recently increased by 2.34%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInovio Pharmaceuticals does not currently pay a dividend.Dividend GrowthInovio Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.76 News SentimentInovio Pharmaceuticals has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Inovio Pharmaceuticals this week, compared to 8 articles on an average week.Search Interest38 people have searched for INO on MarketBeat in the last 30 days. This is an increase of 192% compared to the previous 30 days.MarketBeat Follows10 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inovio Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders1.70% of the stock of Inovio Pharmaceuticals is held by insiders.Percentage Held by Institutions26.79% of the stock of Inovio Pharmaceuticals is held by institutions.Read more about Inovio Pharmaceuticals' insider trading history. Receive INO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INO Stock News HeadlinesINOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights1 hour ago | prnewswire.comStreet Calls of The WeekNovember 9 at 9:17 AM | finance.yahoo.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 10 at 1:00 AM | Base Camp Trading (Ad)Inovio Pharmaceuticals (INO) Expected to Announce Earnings on TuesdayNovember 9 at 1:56 AM | americanbankingnews.comTraders Purchase High Volume of Put Options on Inovio Pharmaceuticals (NASDAQ:INO)November 8 at 1:21 AM | americanbankingnews.comInovio Pharmaceuticals Shares Fall After Pricing $75 Million OfferingNovember 6, 2026 | marketscreener.comMInovio stock tumbles 25% on $75M share offeringNovember 6, 2026 | finance.yahoo.comINOVIO Prices $75 Mln Public Offering With Shares At $1.05 Each; Stock Down 21% PremarketNovember 6, 2026 | rttnews.comSee More Headlines INO Stock Analysis - Frequently Asked Questions How have INO shares performed this year? Inovio Pharmaceuticals' stock was trading at $1.74 at the beginning of 2026. Since then, INO shares have decreased by 16.4% and is now trading at $1.4550. How were Inovio Pharmaceuticals' earnings last quarter? Inovio Pharmaceuticals, Inc. (NASDAQ:INO) posted its quarterly earnings data on Wednesday, August, 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.15. Read the conference call transcript. When did Inovio Pharmaceuticals' stock split? Inovio Pharmaceuticals shares reverse split on the morning of Thursday, January 25th 2024.The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are Inovio Pharmaceuticals' major shareholders? Top institutional investors of Inovio Pharmaceuticals include Green Alpha Advisors LLC (0.11%), LexAurum Advisors LLC (0.09%), Prime Capital Investment Advisors LLC (0.07%) and HighTower Advisors LLC (0.03%). View institutional ownership trends. How do I buy shares of Inovio Pharmaceuticals? Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inovio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inovio Pharmaceuticals investors own include Moderna (MRNA), Tesla (tsla), Novavax (NVAX), Advanced Micro Devices (AMD), NVIDIA (NVDA), NIO (NIO) and Gilead Sciences (GILD). Company Calendar Last Earnings8/12/2026Today11/10/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 8 days, INO's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INO CIK1055726 Webwww.inovio.com Phone(858) 410-3134Fax267-440-4242Employees112Year Founded1979Price Target and Rating Average Price Target for Inovio Pharmaceuticals$5.67 High Price Target$8.00 Low Price Target$4.00 Potential Upside/Downside+290.8%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$84.95 million Net MarginsN/A Pretax MarginN/A Return on Equity-669.94% Return on Assets-73.97% Debt Debt-to-Equity RatioN/A Current Ratio1.00 Quick Ratio1.00 Sales & Book Value Annual Sales$60 thousand Price / Sales2,498.83 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book4.03Miscellaneous Outstanding Shares103,400,000Free Float108,309,000Market Cap$149.93 million OptionableOptionable Beta1.71 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:INO) was last updated on 11/10/2026 by MarketBeat.com Staff. From Our PartnersBlack Friday Bombshell (for traders)For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredIt’s now or neverAnthropic's Claude now generates more revenue than ChatGPT, and the company is about to go public at a $1.5 tr...Paradigm Press | SponsoredThe One AI Stock to Watch in 2027In 2019, Charles Mizrahi named Marvell Technology his top AI pick. It's since climbed 700 percent. Now he's...Prosperity Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
